Enrollment for efficacy trial of COVID-19 vaccine begins

Published On: October 7, 2021 11:48 AM NPT By: Republica  | @RepublicaNepal

KATHMANDU, Oct 7: Enrollment for Sanofi and GSK’s Phase 3 efficacy trial of COVID-19 vaccine has started in Nepal.

Sanofi and GSK received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy and immunogenicity of their adjuvant recombinant-protein COVID-19 vaccine candidate.

The International Vaccine Institute (IVI), an international organization dedicated to the discovery, development and delivery of safe, effective and affordable vaccines, will conduct the Phase 3 clinical trial in Nepal, with an aim of enrolling 4,000 volunteers across 3 study sites in the country.



Leave A Comment